LEADS BioLabs

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
 LEADS Biolabs is a world-class cancer immune-therapy company based in Nanjing, China.
The company was founded in 2014 by two leading scientists, Dr. Xiaoqiang Kang, MD PhD and Dr. Shoupeng Lai PhD
 LEADS currently have 5 leading cancer immunology oncology assets for solid tumors, each at various clinical stages. LEADS is interested in looking for out-licensing or potential collaborative
partnerships to further develop these assets.
 Diverse assets pipeline
Products to address solid tumors include an alphaLAG-3 mAb (LBL-007), alphaTIM-3 (LBL-003), alphaPD-1/TGFbR bsAb (LBL-015), alphaPD-L1/4-1BB bsAb (LBL-024) and TNFR2 mAb (LBL-019)
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
LBL-007 (anti-LAG-3 mAb)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5-7
Speaker
photo
EVP/ Co-founder
LEADS BioLabs